Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 114


Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.

Escuriola Ettingshausen C, Hegemann I, Simpson ML, Cuker A, Kulkarni R, Pruthi RK, Garly ML, Meldgaard RM, Persson P, Klamroth R.

Res Pract Thromb Haemost. 2019 Mar 23;3(2):268-276. doi: 10.1002/rth2.12192. eCollection 2019 Apr.


Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.

Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S.

Am J Hematol. 2019 Jun;94(6):697-709. doi: 10.1002/ajh.25475. Epub 2019 Apr 16. Review.


Why plasma-derived factor VIII?

Aledort L, Carpenter SL, Cuker A, Kulkarni R, Recht M, Young G, Leissinger C.

Haemophilia. 2019 Mar 13. doi: 10.1111/hae.13705. [Epub ahead of print] No abstract available.


Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.

Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612. [Epub ahead of print]


Structured decision-making drives guidelines panels' recommendations "for" but not "against" health interventions.

Djulbegovic B, Reljic T, Elqayam S, Cuker A, Hozo I, Zhou Q, Li SA, Alexander P, Nieuwlaat R, Wiercioch W, Sch√ľnemann H, Guyatt G.

J Clin Epidemiol. 2019 Jun;110:23-33. doi: 10.1016/j.jclinepi.2019.02.009. Epub 2019 Feb 16.


Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.

Coppo P, Cuker A, George JN.

Res Pract Thromb Haemost. 2018 Nov 16;3(1):26-37. doi: 10.1002/rth2.12160. eCollection 2019 Jan. Review.


Clinical and laboratory diagnosis of TTP: an integrated approach.

Chiasakul T, Cuker A.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):530-538. doi: 10.1182/asheducation-2018.1.530. Review.


American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N.

Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. Review.


Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia.

Pishko AM, Fardin S, Lefler DS, Paydary K, Vega R, Arepally GM, Crowther M, Rice L, Cines DB, Cuker A.

Blood Adv. 2018 Nov 27;2(22):3155-3162. doi: 10.1182/bloodadvances.2018023077.


How can we reverse bleeding in patients on direct oral anticoagulants?

Crowther M, Cuker A.

Kardiol Pol. 2019;77(1):3-11. doi: 10.5603/KP.a2018.0197. Epub 2018 Oct 19.


Evidence to Decision framework provides a structured "roadmap" for making GRADE guidelines recommendations.

Li SA, Alexander PE, Reljic T, Cuker A, Nieuwlaat R, Wiercioch W, Guyatt G, Sch√ľnemann HJ, Djulbegovic B.

J Clin Epidemiol. 2018 Dec;104:103-112. doi: 10.1016/j.jclinepi.2018.09.007. Epub 2018 Sep 22.


Neutrophil accumulation and NET release contribute to thrombosis in HIT.

Gollomp K, Kim M, Johnston I, Hayes V, Welsh J, Arepally GM, Kahn M, Lambert MP, Cuker A, Cines DB, Rauova L, Kowalska MA, Poncz M.

JCI Insight. 2018 Sep 20;3(18). pii: 99445. doi: 10.1172/jci.insight.99445. eCollection 2018 Sep 20.


The role of scientific publishing in the development of early career investigators.

Cuker A, Ay C, Cushman M.

Res Pract Thromb Haemost. 2017 Dec 27;2(1):6-7. doi: 10.1002/rth2.12072. eCollection 2018 Jan. No abstract available.


T2 Magnetic Resonance to Monitor Hemostasis.

Cuker A, Marturano JE, Carinato ME, Lowery TJ, Cines DB.

Semin Thromb Hemost. 2019 Apr;45(3):247-252. doi: 10.1055/s-0038-1667114. Epub 2018 Aug 17.


The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis.

Chiasakul T, Cuker A.

Blood Adv. 2018 Jul 24;2(14):1799-1802. doi: 10.1182/bloodadvances.2018018622. Review. No abstract available.


A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.


Clot stability as a determinant of effective factor VIII replacement in hemophilia A.

Leong L, Chernysh IN, Xu Y, Sim D, Nagaswami C, de Lange Z, Kosolapova S, Cuker A, Kauser K, Weisel JW.

Res Pract Thromb Haemost. 2017 Oct;1(2):231-241. doi: 10.1002/rth2.12034. Epub 2017 Aug 10.


Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.

Grant SJ, Kothari S, Gimotty PA, Gooneratne NS, Cuker A.

J Thromb Thrombolysis. 2018 Jul;46(1):1-6. doi: 10.1007/s11239-018-1651-0.


Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists.

Pishko AM, Misgav M, Cuker A, Cines DB, George JN, Vesely SK, Terrell DR.

J Thromb Thrombolysis. 2018 Jul;46(1):24-30. doi: 10.1007/s11239-018-1649-7.


Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.

Cuker A.

Am J Hematol. 2018 Jun;93(6):816-823. doi: 10.1002/ajh.25092. Epub 2018 Apr 15. Review.

Supplemental Content

Loading ...
Support Center